Most cell therapies begin with a blood draw and a clean-room wait. Chemists at MIT sketch a different route: fatty nanoparticles that carry instructions into natural killer cells while those cells stay inside the patient, turning them into CAR NK hunters on the spot.
Their quarry is broken T cells — the kind behind certain lymphomas and autoimmune hepatitis. Classic CAR T products struggle here because rewritten T cells can attack one another. Killer cells avoid that fratricide, yet building CAR NK batches outside the body has stayed slow and expensive. A bedside infusion of particles could cut both cost and delay, argues senior author Daniel Anderson.
Tiny antibody pieces stuck to each particle steer them toward NK receptors. Animal tests showed most of the intended killers — roughly four in five — accepted the new genetic brief. Aggressive melanoma models saw complete clearances in three of five treated animals. Humanized mice carrying T-cell lymphoma lost their tumours after a short course of five shots, matching results from conventionally manufactured CAR NK cells.
In an autoimmune hepatitis model, one dose was enough: the rogue T cells vanished and liver tissue recovered. Postdoc Yuang Chen co-led the work with graduate researchers Julia Monkovic and Haseeb Mughal; veteran engineer Robert Langer also signed the paper. Money for the project arrived from the drugmaker Sanofi, from MIT’s own Marble nanomedicine centre, and from federal cancer-research core support. Nature Biotechnology carries the study.
Regulators have yet to green-light any CAR NK product, so the findings remain animal-stage. If people tolerate the approach, similar in-body reprogramming might later reach other T-cell-driven illnesses such as multiple sclerosis or rheumatoid arthritis.
